A detailed history of Aigen Investment Management, LP transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Aigen Investment Management, LP holds 6,367 shares of REGN stock, worth $4.54 Million. This represents 0.85% of its overall portfolio holdings.

Number of Shares
6,367
Previous 723 780.64%
Holding current value
$4.54 Million
Previous $760,000 496.71%
% of portfolio
0.85%
Previous 0.16%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 06, 2025

BUY
$701.85 - $1046.91 $3.96 Million - $5.91 Million
5,644 Added 780.64%
6,367 $4.54 Million
Q3 2024

Nov 05, 2024

BUY
$1024.09 - $1201.76 $740,417 - $868,872
723 New
723 $760,000
Q1 2024

May 14, 2024

SELL
$902.69 - $993.35 $120,960 - $133,108
-134 Reduced 20.4%
523 $503,000
Q4 2023

Feb 09, 2024

BUY
$775.18 - $881.7 $509,293 - $579,276
657 New
657 $577,000
Q2 2022

Aug 02, 2022

SELL
$548.35 - $738.84 $661,310 - $891,041
-1,206 Closed
0 $0
Q1 2022

May 05, 2022

SELL
$595.12 - $698.43 $3.56 Million - $4.17 Million
-5,977 Reduced 83.21%
1,206 $842,000
Q4 2021

Feb 11, 2022

BUY
$543.48 - $670.97 $182,065 - $224,774
335 Added 4.89%
7,183 $4.5 Million
Q3 2021

Nov 12, 2021

SELL
$574.03 - $680.96 $2.16 Million - $2.57 Million
-3,771 Reduced 35.51%
6,848 $4.14 Million
Q2 2021

Aug 10, 2021

BUY
$472.8 - $558.54 $5.02 Million - $5.93 Million
10,619 New
10,619 $5.93 Million
Q1 2021

May 11, 2021

SELL
$446.73 - $548.2 $667,414 - $819,010
-1,494 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$478.3 - $607.98 $714,580 - $908,322
1,494 New
1,494 $722,000
Q2 2020

Aug 10, 2020

SELL
$493.32 - $643.92 $4,933 - $6,439
-10 Closed
0 $0
Q1 2020

May 08, 2020

BUY
$336.18 - $494.43 $3,361 - $4,944
10 New
10 $5,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $76.5B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Aigen Investment Management, LP Portfolio

Follow Aigen Investment Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Aigen Investment Management, LP with notifications on news.